Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Alfonso Segarra"'
Autor:
Marian Goicoechea, Vicente Álvarez, Alfonso Segarra, Manuel Polaina, Guillermo Martín-Reyes, Nicolás Roberto Robles, Verónica Escudero, Cristhian Orellana, Sergio Bea Granell, Joaquín de Juan-Ribera, Milagros Fernández Lucas, Jose Maria Graña, Javier Reque, Rosa Sánchez Hernández, Santiago Villamayor, Jose Luis Górriz
Publikováno v:
Nefrología (English Edition), Vol 42, Iss 3, Pp 301-310 (2022)
Background and objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain. Material and Methods: Retrospective,
Externí odkaz:
https://doaj.org/article/2662d6f7624b420eaed22f96c4b9606d
Autor:
Marian Goicoechea, Vicente Álvarez, Alfonso Segarra, Manuel Polaina, Guillermo Martín-Reyes, Nicolás Roberto Robles, Verónica Escudero, Cristhian Orellana, Sergio Bea Granell, Joaquín de Juan-Ribera, Milagros Fernández Lucas, Jose Maria Graña, Javier Reque, Rosa Sánchez Hernández, Santiago Villamayor, Jose Luis Górriz
Publikováno v:
Nefrología, Vol 42, Iss 3, Pp 301-310 (2022)
Resumen: Antecedentes y objetivo: Describir las características clínicas de los pacientes tratados con evolocumab, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades
Externí odkaz:
https://doaj.org/article/5c5696b9aaff41f4be86267f461ae5f7
Autor:
Verónica Escudero, José M. Graña, Milagros Fernández Lucas, Rosa Sánchez Hernández, Vicente Álvarez, Alfonso Segarra, Guillermo Martín-Reyes, Javier Reque, José Luis Górriz, Nicolás Roberto Robles, Marian Goicoechea, Manuel Polaina, Santiago Villamayor, Sergio Bea Granell, Cristhian Orellana, Joaquín de Juan-Ribera
Publikováno v:
Nefrología. 42:301-310
Resumen Antecedentes y objetivo Describir las caracteristicas clinicas de los pacientes tratados con evolocumab, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de
Autor:
Marian Goicoechea, Manuel Polaina, Nicolas-Roberto Robles-Perez, José Luis Górriz, Veronica Escudero Quesada, Santiago Villamayor, Guillermo Martín, Vicente Álvarez, Cristhian Orellana, Alfonso Segarra
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Cardiovascular disease is the primary cause of morbidity and mortality in patients with chronic kidney disease (CKD). Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowe
Autor:
Gema Fernández-Juárez, Jorge Rojas-Rivera, Anne-Els van de Logt, Joana Justino, Angel Sevillano, Fernando Caravaca-Fontán, Ana Ávila, Cristina Rabasco, Virginia Cabello, Alfonso Varela, Montserrat Díez, Guillermo Martín-Reyes, Marian Goicoechea Diezhandino, Luis F. Quintana, Irene Agraz, Juan Ramón Gómez-Martino, Mercedes Cao, Antolina Rodríguez-Moreno, Begoña Rivas, Cristina Galeano, Jose Bonet, Ana Romera, Amir Shabaka, Emmanuelle Plaisier, Mario Espinosa, Jesus Egido, Alfonso Segarra, Gérard Lambeau, Pierre Ronco, Jack Wetzels, Manuel Praga, Fernando Caravaca-Fontan, Hernando Trujillo, Eduardo Gutiérrez, Gema Fernandez Juarez, Alberto Ortiz, Marian Goicoechea, Úrsula Verdalles, Alfons Segarra, Lara Perea, Ildefonso Valera, Mónica Martín, Miguel Angel Pérez Valdivia, Miquel Blasco, Andrés López Muñiz, Ana Avila, Tamara Malek, Montserrat Diaz, Iara DaSilva, Jordi Bonet, Maruja Navarro, Ana Huerta, Ezequiel Rodríguez-Paternina, Ana Vigil, Roberto Alcázar, Vicente Paraíso, Vicente Barrio, Julia Hofstra
Publikováno v:
Scientia
Kidney International
Kidney International, 2021, 99 (4), pp.986-998. ⟨10.1016/j.kint.2020.10.014⟩
Kidney International, Nature Publishing Group, 2021, 99 (4), pp.986-998. ⟨10.1016/j.kint.2020.10.014⟩
Kidney International, 99, 4, pp. 986-998
Kidney International, 99, 986-998
Kidney International
Kidney International, 2021, 99 (4), pp.986-998. ⟨10.1016/j.kint.2020.10.014⟩
Kidney International, Nature Publishing Group, 2021, 99 (4), pp.986-998. ⟨10.1016/j.kint.2020.10.014⟩
Kidney International, 99, 4, pp. 986-998
Kidney International, 99, 986-998
Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER); Red de Investigación Renal (RedInRen); European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); Fundación Renal Iñigo Álvarez de Toledo (FRIAT); Fundación par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7101c80894df59bc6a357ab4fc59787
https://hdl.handle.net/11351/6922
https://hdl.handle.net/11351/6922
Autor:
Immaculada Comas-Reixach, José-Bruno Montoro-Ronsano, Josep-Maria Suñé-Negre, Albert Blanco-Grau, Alfonso Segarra-Medrano, Maria-Eugenia Palacio-Lacambra
Publikováno v:
British Journal of Clinical Pharmacology. 84:2120-2128
Aims Accurately estimating kidney function is essential for the safe administration of renally cleared drugs such as ganciclovir. Current practice recommends adjusting renally eliminated drugs according to the Cockcroft-Gault equation. There are no d
Autor:
María Azucena Vicente Molina, Elias Jatem, Clara Carnicer, Cristina Martínez, Marisa Martin, Carme Perich, Alfonso Segarra
Publikováno v:
Clinical laboratory. 65(6)
Background Urinary levels of EGF may be a noninvasive biomarker of the degree of interstitial fibrosis. However, all the available data are based on studies that examined the EGF/creatinine ratio in spot urine samples. The agreement between EGF/creat
Publikováno v:
Clinical Laboratory. 65
Background Urinary levels of epidermal growth factor to creatinine ratio are considered as an early predictor of interstitial kidney fibrosis but so far no data are available on their biological variation (BV) and derived parameters. The aim of this
Autor:
Medrano, Alfonso Segarra1 (AUTHOR) alsegarr@gmail.com, Escalante, Elias Jatem1,2 (AUTHOR) alsegarr@gmail.com, Cáceres, Clara Carnicer2 (AUTHOR), Pamplona, Irene Agraz1 (AUTHOR) alsegarr@gmail.com, Allende, Maria Teresa Salcedo3 (AUTHOR), Terrades, Natalia Ramos1 (AUTHOR) alsegarr@gmail.com, Carmeno, Naiara Valtierra1,2 (AUTHOR), Roldán, Elena Ostos1,2 (AUTHOR), Agudelo, Karla Viviana Arredondo1 (AUTHOR) alsegarr@gmail.com, Vasquez, Juliana Jaramillo1 (AUTHOR)
Publikováno v:
Biomarkers. Feb2015, Vol. 20 Issue 1, p77-83. 7p.
Autor:
Alfonso Segarra Medrano, Elías Jatem Escalante, Elena Ostos Roldán, Natalia Ramos Terrades, Karla Viviana Arredondo Agudelo, Irene Agraz Pamplona, Naiara Valtierra Carmeno, Maria Teresa Salcedo Allende, Juliana Jaramillo Vasquez, Clara Carnicer Cáceres
Publikováno v:
Biomarkers. 20:77-83
Context: The dynamics of anti-phospholipase A2 antibody titers during treatment could predict clinical responses in patients with membranous nephropathy.Objectives: We analyzed the predictive value of the dynamics of these antibodies on clinical resp